[Breaking] Cosmax Shares Surge Over 10%, Volatility Interruption Triggered Intraday... Whether Gains Will Hold Draws Attention
Cosmax surged more than 10% during trading on the 6th, triggering the Volatility Interruption (VI) mechanism. At the time the VI was triggered, Cosmax shares stood at 297,500 won, up 27,500 won from the previous day's close of 270,000 won, a gain of approximately 10.19%. The stock, which had falle
![[Breaking] Cosmax Shares Surge Over 10%, Volatility Interruption Triggered Intraday... Whether Gains Will Hold Draws Attention](/_next/image?url=https%3A%2F%2Fmedia.cbcglobe.com%2Ftenants%2Fcbc00000-0000-4000-8000-000000000001%2Fmedia%2Fcbc%2F2026%2F06%2F581419%2F479dac739b049517%2Foriginal.webp&w=1920&q=75)
Cosmax surged more than 10% during trading on the 6th, triggering the Volatility Interruption (VI) mechanism.
At the time the VI was triggered, Cosmax shares stood at 297,500 won, up 27,500 won from the previous day's close of 270,000 won, a gain of approximately 10.19%.
The stock, which had fallen the previous day, turned upward today, showing a rebound trend. The key question now is how long the upward momentum will last. Although the share price posted a double-digit intraday gain, the VI trigger alone does not guarantee that strength will persist through the close. How much of the gain is maintained after trading resumes will be the main factor in judging the day's stock price trend.
[This article was written with AI assistance based on market price information and is for informational purposes only. It does not recommend buying or selling any specific stock. Intraday prices are subject to change, so investors should check the latest market prices and disclosures. Responsibility for investment decisions and their outcomes rests with the investor.]
CBC Globe publishes verified stories with editorial review, source checks, and tenant-specific publication standards.

![[Breaking] Static VI Triggered for POSCO Future M... Trigger Price 206,000 Won, Deviation Rate +10.21%](/_next/image?url=https%3A%2F%2Fmedia.cbcglobe.com%2Ftenants%2Fcbc00000-0000-4000-8000-000000000001%2Fmedia%2Fcbc%2F2026%2F07%2F589778%2Fec923b3971f7148e%2Fvariants%2Fhero.webp&w=1920&q=75)
![[Breaking] ST Pharm Receives Phase 2a Clinical Study Report for HIV-1 Treatment STP0404, Confirming Maximum Viral Reduction of -1.61 log10](/_next/image?url=https%3A%2F%2Fmedia.cbcglobe.com%2Ftenants%2Fcbc00000-0000-4000-8000-000000000001%2Fmedia%2Fcbc%2F2026%2F06%2F581911%2Fa630da1c47d6049c%2Fvariants%2Fhero.webp&w=1920&q=75)
